Stock Events

Stock Events

Alkermes 

$55.22
45
+$0.08+0.15% Tuesday 20:00
-$0.01-0.02%Tuesday 23:06After hours

Statistics

Day High
55.52
Day Low
54.45
52W High
55.67
52W Low
25.17
Volume
93,841
Avg. Volume
-
Mkt Cap
9.2B
P/E Ratio
61.27
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.55
-0.01
0.52
1.05
Expected EPS
-0.016692
Actual EPS
N/A

Financials

16.37%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.48BRevenue
241.66MNet Income

Analyst Ratings

51.70Average Price Target
The highest estimate is 65.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALKS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, competes in the pharmaceuticals market, including CNS and mental health treatments, similar to Alkermes' focus areas.
Lilly(Eli) &
LLY
Mkt Cap1.08T
Eli Lilly and Company competes directly with Alkermes in the psychiatric and neurological drug markets, including treatments for depression and schizophrenia.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. offers products in various therapeutic areas that overlap with Alkermes, including treatments for mental health conditions.
Novartis
NVS
Mkt Cap305.1B
Novartis AG competes in the neuroscience segment, offering medications for neurological conditions, directly competing with Alkermes' portfolio.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. has a range of pharmaceutical products that compete with Alkermes, especially in the areas of health and well-being, including treatments for conditions affecting the central nervous system.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol-Myers Squibb Company has a diverse biopharmaceutical portfolio that includes psychiatric and neurological medications, competing with Alkermes.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.34B
Teva Pharmaceutical Industries Limited manufactures generic and specialty medicines, including CNS and neurology products, competing with Alkermes.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. competes with Alkermes in the neuroscience area, including R&D and marketing of psychiatric and neurological drugs.
Biogen
BIIB
Mkt Cap31.91B
Biogen Inc. focuses on neurology and has a strong presence in the neuroscience field, making it a direct competitor to Alkermes in areas like multiple sclerosis and psychiatric disorders.
AMGEN
AMGN
Mkt Cap201.93B
Amgen Inc. competes in the biopharmaceutical field, focusing on innovative treatments that could overlap with Alkermes' work in CNS disorders.

About

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Show more...
CEO
Mr. Richard F. Pops
Employees
2095
Country
Ireland
ISIN
IE00B56GVS15

Listings

XETRA
DE
8AK.XETRA
MU
DE
8AK.MU
STU
DE
8AK.STU
F
DE
8AK.F

0 Comments

Share your thoughts

FAQ

What is Alkermes stock price today?▼
The current price of ALKS is $55.22 USD — it has increased by +0.15% in the past 24 hours. Watch Alkermes stock price performance more closely on the chart.
What is Alkermes stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alkermes stocks are traded under the ticker ALKS.
Is Alkermes stock price growing?▼
ALKS stock has risen by +6.77% compared to the previous week, the month change is a +30.08% rise, over the last year Alkermes has showed a +87.95% increase.
What is Alkermes market cap?▼
Today Alkermes has the market capitalization of 9.2B
When is the next Alkermes earnings date?▼
Alkermes is going to release the next earnings report on July 29, 2026.
What were Alkermes earnings last quarter?▼
ALKS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.55 USD resulting in a +26.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alkermes revenue for the last year?▼
Alkermes revenue for the last year amounts to 1.48B USD.
What is Alkermes net income for the last year?▼
ALKS net income for the last year is 241.66M USD.
How many employees does Alkermes have?▼
As of July 08, 2026, the company has 2,095 employees.
In which sector is Alkermes located?▼
Alkermes operates in the Health & Wellness sector.
When did Alkermes complete a stock split?▼
The last stock split for Alkermes was on May 15, 2000 with a ratio of 2:1.
Where is Alkermes headquartered?▼
Alkermes is headquartered in Dublin, Ireland.